DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Revenue of DermTech, Inc. (DMTK)
Revenue in 2023 (TTM): $15.3 M
According to DermTech, Inc.'s latest financial reports the company's current revenue (TTM) is $15.3 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of DermTech, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $15.3 M | $276 K | $-97,893,000 | $-100,888,000 | $-100,888,000 |
| 2022 | $14.52 M | $647 K | $-118,306,000 | $-116,683,000 | $-113,719,000 |
| 2021 | $11.84 M | $1.27 M | $-76,310,000 | $-78,335,000 | $-76,976,000 |
| 2020 | $5.89 M | $-96,000 | $-35,289,000 | $-35,249,000 | $-34,723,000 |
| 2019 | $3.36 M | $60 K | $-17,960,000 | $-19,689,000 | $-21,902,000 |
| 2018 | $ | $-306,243 | $-260,827 | $856.41 K | $856.41 K |
| 2017 | $ | $ | $-60 | $-60 | $-60 |